Table 1.
Patient and tumor characteristics for the 359 tumors
| Number of tumors | 359 |
| Number of primary tumors | 346 |
| Number of primary BRCA1-mutated tumors | 17 |
| Number of primary BRCA2-mutated tumors | 31 |
| Number of primary familial non-BRCA1/2 tumors | 126 |
| Tumor size | |
| ≤20 mm | 145 (45%) |
| > 20 mm | 175 (55%) |
| Mean size mm (SD) | 25.8 (15) |
| Histologic grading | |
| Grade 1 | 26 (11%) |
| Grade 2 | 100 (43%) |
| Grade 3 | 106 (46%) |
| Estrogen-receptor status | |
| Positive | 227 (66%) |
| Negative | 119 (34%) |
| Progesterone-receptor status | |
| Positive | 194 (57%) |
| Negative | 149 (43%) |
| Lymph-node status | |
| Negative | 190 (58%) |
| Positive | 137 (42%) |
| Age | |
| Median age, years (range) | 49 (27-88) |
| < 50 years | 182 (51%) |
| ≥ 50 years | 174 (49%) |
| Classification according to Hu et al. [4] | |
| Basal-like | 79 (22%) |
| Normal-like | 34 (9%) |
| HER2-enriched | 34 (9%) |
| Luminal A | 95 (26%) |
| Luminal B | 70 (19%) |
| Unclassified | 47 (13%) |
| Overall survival | |
| Median overall survival in years (range) | 8.1 (0.24-32) |
| Median overall survival in years for patients still alive (range) | 12.8 (1.55-20.2) |
Survival is given for the 346 patients from whom primary tumors were available.